Hepatitis E vaccine study in healthy adults, children, and people with HIV
Part of Digestive system, Infections clinical trials.
This study tests a hepatitis E vaccine called Hecolin in healthy people (ages 2–45) and in adults (18–45) living with HIV who are on antiviral treatment. It aims to see how well the vaccine works and if it's safe for different groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 45 years old (if you are HIV negative) or between 18 and 45 (if you have HIV and are on antiviral treatment).
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study. If you are of childbearing age, you need to use effective birth control until 8 months after the first dose (or 3 months after the last dose for HIV-positive participants).
- You must not have received a hepatitis E vaccine before.
- You need to be in generally good health and willing to follow study procedures and provide blood samples.
- You cannot have a fever (100.4°F or higher) or be sick within 3 days before vaccination, or have severe allergies, immune problems, or certain medical conditions (like bleeding disorders or very high weight).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new hepatitis B vaccine to see if it is safe and helps the body fight the virus. It is for healthy people who have not had a hepatitis B vaccine in the last 10 years.
This study tests a new vaccine designed to prevent hepatitis C, a virus that affects the liver. The goal is to see if the vaccine is safe, and to understand how the body's immune system responds to it.
This trial tests a new hepatitis A vaccine in healthy people aged 1 year and older. It aims to see how well the vaccine prevents hepatitis A and checks for any side effects.
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study tests an experimental vaccine designed to protect against E. coli bacteria. It is for healthy adults aged 18 to 63 who want to help researchers see if the vaccine is safe and produces an immune response.
Hear when a new Hepatitis E Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.